FGF23/FGFR4-mediated left ventricular hypertrophy is reversible

FGF23 promotes myocardial fibrosis in mice through activation of β-catenin

(2016) Huixin Hao et al.   Oncotarget

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy

(2015) Alexander Grabner et al.   Cell Metabolism

FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability

(2014) Neerupma Silswal et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD

(2014) G. S. Di Marco et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

(2013) Chad D. Touchberry et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study

(2013) Benjamin D. Parker   ANNALS OF INTERNAL MEDICINE

Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults

(2013) Anna Jovanovich et al.   ATHEROSCLEROSIS

Evolving importance of kidney disease: from subspecialty to global health burden

(2013) Kai-Uwe Eckardt et al.   LANCET

Fibroblast Growth Factor Receptor 1 Signaling in Adult Cardiomyocytes Increases Contractility and Results in a Hypertrophic Cardiomyopathy

(2013) Sarah N. Cilvik et al.   PLoS One

Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction

(2013) Gina M. Yanochko et al.   TOXICOLOGICAL SCIENCES

Cardiorenal Syndrome Type 4: A Review

(2013) Anna Clementi et al.   CardioRenal Medicine

Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease

(2012) Dao-Fu Dai et al.   ANTIOXIDANTS & REDOX SIGNALING

FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality

(2012) Victoria Shalhoub et al.   JOURNAL OF CLINICAL INVESTIGATION

Update on fibroblast growth factor 23 in chronic kidney disease

(2012) Myles Wolf   KIDNEY INTERNATIONAL

Fibroblast Growth Factor 23, Cardiovascular Disease Risk Factors, and Phosphorus Intake in the Health Professionals Follow-up Study

(2011) O. M. Gutierrez et al.   Clinical Journal of the American Society of Nephrology

FGF23 induces left ventricular hypertrophy

(2011) Christian Faul et al.   JOURNAL OF CLINICAL INVESTIGATION

Cardioprotective effect of calcineurin inhibition in an animal model of renal disease

(2010) Giovana S. Di Marco et al.   EUROPEAN HEART JOURNAL

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population

(2009) Majd A.I. Mirza et al.   ATHEROSCLEROSIS

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

(2009) Orlando M. Gutiérrez et al.   CIRCULATION

Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis

(2009) P. S. Parfrey et al.   Clinical Journal of the American Society of Nephrology

The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis

(2009) M. Shawkat Razzaque   Nature Reviews Endocrinology

FGFR3 and FGFR4 Do not Mediate Renal Effects of FGF23

(2008) S. Liu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

(2008) Orlando M. Gutiérrez et al.   NEW ENGLAND JOURNAL OF MEDICINE